****New release September 2010****

**MarketVIEW: Tick-borne encephalitis (TBE) vaccines (CAT: VAMV022)**

**Proposal No/#PO**: [Enter client specific #PO]

**Product Name**: MarketVIEW: Tick-borne encephalitis vaccines – Global market forecast

**Project Initiation Date**: n/a

**Billable days**: n/a

**Initiator(s)**: [Enter client name, function and address]

**Therapeutic Area**: Endemic vaccines

**Product (if applicable)**: CAT No: VAMV022, published September 2010

**Background**

Tick-borne encephalitis virus (TBEV) is the causative agent of tick-borne encephalitis (TBE), a potentially fatal neurological infection. The virus is transmitted to humans through the bite of infected *Ixodes* tick species which are endemic to a large area stretching from Southern Germany, across Russia to the islands of Northern Japan. Inactivated whole virus vaccines are licensed in Europe to prevent TBE and given to populations at risk in various countries. Novartis Vaccines, Baxter vaccines and Russian local companies are the major manufacturers of TBE vaccines.

This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of TBE vaccines across endemic markets to 2030. The model contains value ($ m) and volume (mio doses) predictions for each country and discusses current dynamics in disease incidence and possible market upside scenarios.
Methodology

VacZine Analytics has closely monitored all significant source material pertaining to Tick-borne encephalitis (TBE) epidemiology/vaccines. Example, secondary source materials used are literature articles, government websites/databases, medical bodies and associations, conference proceedings and previously analyses (where publically available). Previously published research by VacZine Analytics in field of endemic vaccines has also been utilised.

PRODUCT CONTENTS:
Published September 2010 (CAT No: VAMV022)

****This product is composed of a model and summary presentation

Contents – Summary presentation (MS PowerPoint based)
Author’s note
Executive Summary
Total available market: TBE vaccines ($ 000s) to 2030
Total predicted demand: TBE vaccines (doses 000s)
Total available market per country: TBE vaccines ($ 000s) to 2030
TBE: background
Areas of known TBE endemicity
Clinical features of TBE
TBE epidemiology
Changes in disease incidence
TBE vaccines
Summary of TBE vaccine characteristics
Vaccine target populations
National vaccine policies
Estimated vaccination coverage
Summary of TBE dynamics by country
Major commercial model assumptions
Commercial model assumptions by country
Pricing assumptions
TBE vaccine pipeline
TBE risk areas
Belarus
Croatia
Germany
Hungary
Poland
Slovakia
Switzerland
Sweden
Annual number of vaccinations/volume
TBE vaccines sales/volumes
Bibliography
About VacZine Analytics
Disclaimer

PAGES: 55 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form
Contents – Vaccine demand model (MS Excel-based)

Title sheet
Total charts
Charts value
Charts volume
Value summary (TOTAL MARKET)
Volume summary (TOTAL MARKET)
Austria (Base)
Belarus (Base)
Croatia (Base)
Hungary (Base)
Latvia (Base)
Lithuania (Base)
Poland (Base)
Russia (Base)
Slovakia (Base)
Slovenia (Base)
Sweden (Base)
Switzerland (Base)
National Populations
Source material
Cases
Incidence Rates
Populations at risk
Upside countries
Back-page

WORKSHEETS: ~30
PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- **USD $7995.00/ GBP £5499.00 (Region license)**

*A region is North America, Europe or ROW
For orders in the UK, VAT at 17.5% will be added to final invoice total

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the TERMS and CONDITIONS of purchase.

---

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and the “spiral logo” are UK Registered Trademarks, 2009
BIBLIOGRAPHY:


23. SFME: Risikogebiete in Deutschland (Stand: April 2010). Epi Bull. 2010;5


27. FSME: Risikogebiete in Deutschland (Stand: April 2010). Epi Bull. 2010;17


42. Poland Provinces. Available at: http://www.citypopulation.de/Poland-Cities.html. Accessed: September 2010


TERMS and CONDITIONS:
VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.
3. Cancellation policy. The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. Cancellation rights: For finished documents - a Clients cancellation rights will last for seven working days counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.
5. Invoicing will 100% after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within thirty days of the invoice date.
7. All proposals are quoted in $USD dollars or £GBP and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master TERMS and CONDITIONS available upon request.

VacZine Analytics
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com
About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009